department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Journavx · pharmadog

pharmadog
drugs
Journavx

drug · small molecule

patient view →

suzetrigine

Marketedupdated 2mo ago

by $VERX Vertex, Inc.🔗 ChEMBL

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 2 investigational indications.

all catalysts(2)

approval · 2

JOURNAVX (SUZETRIGINE) — FDA approval

JOURNAVX (SUZETRIGINE) — FDA approval

News(0)

no news has mentioned this drug yet

brand

Journavx

generic

suzetrigine

MOA

12.1 Mechanism of Action Suzetrigine is a selective blocker of the Na V 1.8 voltage-gated sodium channel, compared to other known voltage-gated sodium channels (Na V 1.1 through 1.9). Na V 1.8 is expressed in peripheral sensory neurons including dorsal root ganglion neurons, where its role is to transmit pain signals (action potentials). By selectively inhibiting Na V 1.8 channels, suzetrigine inhibits transmission of pain signals to the spinal cord and brain. M6-SUZ, a major active metabolite, is a less potent inhibitor of Na V 1.8 than suzetrigine by 3.7-fold.

indication

Diabetic Peripheral Neuropathy

phase

marketed

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Jan 30, 2030

~3.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (1)

Dec 4, 2040compositionUS 11834441

FDA exclusivities (1)

Jan 30, 2030NCENew Chemical Entity (5y)3.6y

$VERX12.850.00%

$VERX12.850.00%

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 4

drugJOURNAVX9 co-mentions · 3 sources
tagApproval8 co-mentions · 2 sources
tagSmall Molecule4 co-mentions · 2 sources
tagPain1 co-mentions · 1 sources

Trials studying suzetrigine

phase1Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participantsactive not recruitingn=18
phase3Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgerynot yet recruitingn=100
phase3Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathyrecruitingn=734
phase4Evaluation of Pain Treatment After Total Knee Arthroplastyrecruitingn=60
phase3Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathyrecruitingn=1,100
phase4Suzetrigine for Non-Mastectomy Breast Surgerynot yet recruitingn=120
phase1Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participantsrecruitingn=12
phase3Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)active not recruitingn=455

more trials →